Biotech China 2014

View Profile


Speaking/Presenting-Abstract/Poster at Mtg

Topic Authors / presenters Event name Event date
1. Combined modality targeted therapy of pancreatic cancer with anti-DR5 monoclonal antibody The 2009 NCI Translational Science Meeting November, 2009
2. Combined modality targeted therapy of pancreatic cancer with anti-DR5 monoclonal antibody. The 2009 NCI Translational Science Meeting November, 2009
3. Anti-DR5 Antibody Therapy for Triple Negative Breast Cancer. The 2009 NCI Translational Science Meeting November, 2009
4. Dynamic contrast-enhanced MRI detects early vascular change in orthotopic pancreatic tumor xenografts following anti-EGFR and irinotecan therapies. The Academy of Molecular Imaging Annual Meeting September, 2009
5. Metastasis suppression of pancreatic adenocarcinoma by KISS1 Frontiers of Biomedical Imaging Science‏ meeting June, 2009
6. Team research on monoclonal anti-DR5: from creation to clinical trials UAB Center for Clinical and Translational Science Forum June, 2009
7. Voltage-gated sodium channel blockers for the treatment of prostate cancer cells by inhibiting cell migration, xenograft growth and sensitizing cells to radiation treatment The 2009 AACR Annual Meeting April, 2009
8. KiSS1 re-expression in pancreatic adenocarcinoma in a xenograft mouse model The 2009 AACR Annual Meeting April, 2009
9. Pretargeted radio-immunotherapy 4th International Conference on Translational Research in Radiation Oncology Meeting, March, 2009
10. Dynamic contrast-enhanced MR imaging for early detection of vascular-permeability changes following combination therapy with anti-EGFR antibody and irinotecan in orthotopic pancreatic tumor xenografts: A pilot study. Proc International Society for Magnetic Resonance in Medicine January, 2009
11. Death receptor antibody therapy for anaplastic gliomas Brain Tumor Inter-SPORE MidWinter Retreat January, 2009
12. DDX3 associates with DR5 and negatively regulates apoptosis signal transduction of the death domain NCI Translational Science Meeting November, 2008
13. FNA-based assays predict therapeutic response to TRA-8 (death receptor 5 antibody) treatment in xenograft model of colon and pancreas carcinoma. The 56th Annual Scientific Meeting of the American Society of Cytopathology November, 2008
14. Effect of TRA-8 anti-death receptor 5 antibody in combination with chemotherapy in an ex vivo human ovarian cancer model Proc Comprehensive Cancer Center 2008 Annual Research Retreat November, 2008
15. KiSS1 suppresses metastasis of pancreatic adenocarcinoma in a xenograft mouse model. Proc Comprehensive Cancer Center 2008 Annual Research Retreat November, 2008
16. Treatment of triple negative breast cancer with TRAIL death receptor antibodies and chemotherapy. Proc Comprehensive Cancer Center 2008 Annual Research Retreat November, 2008
17. EMMPRIN as a novel target in head and neck cancer Proc Comprehensive Cancer Center 2008 Annual Research Retreat November, 2008
18. Combined modality targeted therapy of pancreatic cancer with death receptor monoclonal antibodies NCI Translational Science Meeting November, 2008
19. Identification of serum biomarkers of early-stage pancreatic neoplasia using genetically-defined mouse models of pancreatic cancer NCI Translational Science Meeting November, 2008
20. Systemic orthotopic, anti-pancreatic cancer effects in vivo with a novel bispecific ligand-directed toxin delivered using a new method of drug delivery. NCI Translational Science Meeting November, 2008
21. Treatment of SCLC tumors with TRA-8 in combination with cisplatin and radiation. Radiation Research Society Scientific Meeting September, 2008
22. Overexpression of KiSS1 suppresses metastasis in pancreatic adenocarcinoma in a xenograft mouse model The Joint Molecular Imaging Congress September, 2008
23. EMMPRIN as a novel target in head and neck cancer he AAO-HNSF Annual Meeting & OTO EXPO September, 2008
24. KiSS1 overexpression in pancreatic adenocarcinoma in a xenograft mouse model. The Joint Metastasis Research Society-AACR Conference on Metastasis August, 2008
25. TRAIL and TRA-8 anti-DR5 antibody in combination with chemotherapy drugs produce increased cytotoxicity and activate apoptotic pathways in breast cancer cells. Era of Hope Department of Defense Breast Cancer Research Program 2008 Meeting June, 2008
26. Effect of TRA-8 anti-DR5 monoclonal antibody in combination with chemotherapy in an ex vivo human ovarian cancer model The 44th American Society of Clinical Oncology Annual Meeting May, 2008
27. Synergy between radiation, gemcitabine, and agonistic TRAIL-R2 antibody results in survival benefit in an orthotopic pancreatic cancer model The Society for Surgery of the Alimentary Tract Meeting May, 2008
28. Development of explant cytotoxicity assays to predict which patients will respond to TRA-8 treatment. UAB/Daiichi Sankyo Program for Rheumatic Diseases and Cancer Research April, 2008
29. Combination therapy using DR4 and DR5 antibodies, gemcitabine, and radiation inhibits pancreatic cancer growth in an animal model The Academic Surgical Congress Annual Meeting February, 2008
30. Erlotinib reduces FLIP mediated resistance to TRA-8 agonistic TRAIL-R2 antibody in pancreatic cancer cells The Academic Surgical Congress Annual Meeting February, 2008
31. KiSS1 treatment of pancreatic cancer UAB Post-doctoral Research Day February, 2008
32. Treatment of metastatic disease with radiolabeled antibodies . NCI-ASTRO Workshop December, 2007
33. Genetically designing a more potent anti-pancreatic cancer agent by simultaneously cotargeting human IL-13 and EGF receptors in a mouse xenograft model. The 2007 APA Meeting November, 2007
34. Adenovirus armed with tissue inhibitor metalloproteinase-2 potentiates combined chemoradiation therapy of HNSCC in vivo UAB Gene Therapy Retreat 2007 October, 2007
35. Diffusion-weighed MRI evaluates early therapeutic efficacy of a novel anti-DR5 antibody in breast and pancreatic tumor xenografts Proc Comprehensive Cancer Center 2007 Annual Research Retreat October, 2007
36. Anti-TRAIL-R2 antibody synergy with radiation increases survival in an in vivo pancreatic cancer model Proc Comprehensive Cancer Center 2007 Annual Research Retreat October, 2007
37. Epidermal growth factor receptor (EGFR) intron-1 polymorphism and overall survival in patients with pancreatic adenocarcinoma Proc Comprehensive Cancer Center 2007 Annual Research Retreat October, 2007
38. Ex vivo assay predicts therapeutic response to TRA-8 (death receptor 5 antibody) in xenograft model of colon and pancreas carcinoma. Proc Comprehensive Cancer Center 2007 Annual Research Retreat October, 2007
39. Diffusion-weighted MR imaging (DWI) at 9.4T detects early therapeutic efficacy of an anti-DR5 antibody combined with gemcitabine in an orthotopic pancreatic tumor model The AMI/SMI Joint Molecular Imaging Conference September, 2007
40. Development of explant cytotoxicity assays to predict which patients will respond to TRA-8 treatment UAB/Sankyo Program for Rheumatic Diseases and Cancer Research August, 2007
41. Effects of PEGylated curcumin conjugate on pancreatic cancer cell proliferation and apoptosis The 15th SPORE Investigators Workshop July, 2007
42. Death receptor antibody therapy for anaplastic gliomas The 15th SPORE Investigators Workshop July, 2007
43. Pancreatic cancer ErbB3 pathway activation is associated with erlotinib sensitivity in vitro and improved postoperative patient survival The Society of Surgery of the Alimentary Tract Annual Meeting May, 2007
44. Development of explant cytotoxicity assays to predict which patients will respond to TRA-8 treatment UAB/Sankyo Program for Rheumatic Diseases and Cancer Research April, 2007
45. Combination therapy using anti-DR5 TRA-8 monoclonal antibody improves survival in a metastatic pancreatic cancer animal model The 2007 Society of Black Academic Surgeons Annual Meeting April, 2007
46. Pancreatic cancer epidermal growth factor receptor (EGFR) intron 1 polymorphism influences clinical outcome and response to erlotinib The Society of Surgical Oncology Annual Meeting March, 2007
47. Tumor immunology program UAB Comprehensive Cancer Center Retreat February, 2007
48. Analysis of aberrant epidermal growth factor receptor (EGFR) pathway signaling in pancreatic cancer patients: Implications for anti-EGFR therapy. The 2nd Annual Academic Surgical Congress February, 2007
49. Antitumor activity of anti-death receptor 5 monoclonal antibody in combination with chemotherapy in a human cervical cancer model Southern Society for Clinical Investigation Oncology Young Investigator’s Forum February, 2007
50. Combination treatment with an agonistic anti-death receptor-5 antibody (TRA-8) and irinotecan (CPT-11) increases survival in an orthotopic model of pancreatic cancer Academic Surgical Congress February, 2007
51. TRA-8 (TRAIL-R2 antibody) based combination chemotherapy produces a survival benefit in a pancreatic cancer orthotopic model The 2nd Annual Academic Surgical Congress February, 2007
52. Adenovirus armed with tissue inhibitor metalloproteinase-2 potentiates combined chemoradiation therapy of HNSCC in vivo UAB Post-doc Research Day 2007 February, 2007
53. Death receptor antibody treatment of pancreatic cancer UAB SPORE in Pancreatic Cancer Meeting December, 2006
54. Development of explant cytotoxicity assays to predict which patients will respond to TRA-8 treatmen UAB/Sankyo Program for Rheumatic Diseases and Cancer Research November, 2006
55. Treatment of orthotopic pancreatic cancer xenografts with TRA-8 anti-DR5 antibody and chemotherapy Eleventh Conference on Cancer Therapy with Antibodies and Immunoconjugates October, 2006
56. Ultrasound imaging to monitor response of orthotopic pancreatic cancer xenografts treated with TRA-8 anti-DR5 MAb and gemcitabine The Society of Nuclear Medicine 53rd Annual Meeting June, 2006
57. Multi-modality targeted therapy of pancreatic cancer with death receptor monoclonal antibodies and chemotherapy: Radiation interaction GI/Pancreas SPORE Winter Meeting January, 2006
58. Multi-modality targeted therapy of pancreatic cancer with death receptor monoclonal antibodies and chemotherapy: Radiation interaction UAB SPORE in Pancreatic Cancer, Internal Advisory Committee Meeting January, 2006
59. TRAIL receptor targeted therapy AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, November, 2005
60. Treatment of breast cancer with antibodies against tumor necrosis factor-related apoptosis-inducing ligand death receptors in combination with chemotherapy Era of Hope 2005 Department of Defense Breast Cancer Research Program Meeting June, 2005
61. Treatment of breast cancer with antibodies against tumor necrosis factor-related apoptosis-inducing ligand death receptors in combination with chemotherapy Era of Hope Department of Defense Breast Cancer Research Program Meeting June, 2005
62. Multi-modality targeted therapy of pancreatic cancer with death receptor monoclonal antibodies and chemotherapy: Radiation interaction UAB SPORE in Pancreatic Cancer, Internal Advisory Committee Meeting June, 2005
63. Combination therapy of pancreatic cancer using TRA-8 antibody against death receptor 5 and gemcitabine induces apoptosis via different mechanisms The 96th Annual Meeting of the American Association for Cancer Research, April, 2005
64. Tumor immunology program CCC Scientific Priority and Strategic Planning Retreat August, 2004
65. Antitumor efficacy of mTRA-8 anti-DR5 monoclonal antibody against human breast cancer is enhanced by combination chemotherapy The 12th SPORE Investigators Workshop July, 2004
66. Molecular chemotherapy and viral oncolysis of experimental malignant gliomas with ∆g134.5 HSV expressing cytosine deaminase The 12th SPORE Investigators Workshop July, 2004
67. Treatment of breast cancer with TRAIL death receptor antibodies in combination with chemotherapy UAB Breast Cancer SPORE Executive Meeting June, 2004
68. Improved therapy of prostate carcinoma with TRAIL gene delivery using Flt-1 promoter element in combination with ionizing radiation American Society of Gene Therapy Annual Meeting May, 2004
69. Treatment of cancer with death receptor antibodies in combination with chemotherapy and radiation therapy UAB/Sankyo Program for Rheumatic Diseases and Cancer Research April, 2004
70. Gene therapy with TRAIL death receptor antibodies UAB Hematology/Oncology Research Conference February, 2004
71. Multi-modality targeted therapy of pancreatic cancer with death receptor monoclonal antibodies and chemotherapy: Radiation interaction UAB SPORE in Pancreatic Cancer February, 2004
72. Viral and molecular chemotherapy of malignant gliomas Brain Inter-SPORE Meeting January, 2004
73. Phase I pre-targeting radioimmunotherapy of metastatic breast cancer Breast Cancer SPORE Roundtable, November, 2003
74. Treatment of breast cancer xenografts with death receptor antibodies Breast Cancer SPORE Roundtable November, 2003
75. Treatment of cancer with death receptor antibodies in combination with chemotherapy and radiation therapy UAB/Sankyo Program for Rheumatic Diseases and Cancer Research November, 2003
76. Gene expression imaging with radiolabeled ligands 43rd Annual Meeting of Japanese Society of Nuclear Medicine October, 2003
77. Treatment with mTRA-8 anti-DR5 monoclonal antibody with or without chemotherapy inhibits human colon cancer xenograft growth in athymic nude mice. 94th Annual Meeting of the American Association for Cancer Research July, 2003
78. Radiation (XRT) may improve the tumor-selective activation of capecitabine (CAP) by cytokine mediated induction and/or stabilization of thymidine phosphorylase (TP) mRNA: Implications for evaluating CAP and XRT for glioblastoma multiforme (GBM) IBRO Annual Meeting July, 2003
79. New adenoviral vectors for molecular chemotherapy of prostate cancer American Society of Gene Therapy 6th Annual Meeting June, 2003
80. Treatment of cancer with death receptor antibodies in combination with chemotherapy and radiation therapy UAB/Sankyo Program for Rheumatic Diseases Research November, 2002
81. Therapy with death receptor antibodies Comprehensive Cancer Center 2002 Annual Research Retreat October, 2002
82. Overexpression of Bax influences cell cycle regulation in glioblastoma cell lines Cancer Center Annual Research Retreat and Research Competition October, 2002
83. Enhanced efficacy of death receptor antibodies in combination with chemotherapeutic drugs Cancer Center Annual Research Retreat and Research Competition October, 2002
84. Evaluation and modulation of the in vitro efficacy of TRA-8 (monoclonal antibody to DR5) alone and in combination with chemotherapy in colon cancer cell lines. Cancer Center Annual Research Retreat and Research Competition October, 2002
85. Targeted immunotherapy program UAB SPORE in Ovarian Cancer External Advisory Committee Meeting August, 2002
86. Radiation enhancement of viral molecular chemotherapy of malignant gliomas 10th SPORE Investigators Workshop July, 2002
87. Validating the utility of a novel pretargeting approach for intraperitoneal (IP) radioimmunotherapy 10th SPORE Investigators Workshop July, 2002
88. Striking antitumor efficacy of monoclonal antibodies to DR4 and DR5 with or without chemotherapy in a human breast cancer model 10th SPORE Investigators Workshop July, 2002
89. Treatment of tumor xenografts with 177Lu- and 188Re-HuCC49 and HuCC49∆Ch2. 49th Society of Nuclear Medicine Annual Meeting June, 2002
90. Genetic radioimmunotherapy of cancer Modern Imaging Technology: Basic Science in Medical Applications. June, 2002
91. Validating the utility of a novel pretargeting approach for intraperitoneal (IP) radioimmunotherapy (RIT). American Society of Clinical Oncology Annual Meeting May, 2002
92. Treatment of human breast cancer xenografts with monoclonal antibody against DR5 with or without chemotherapy inhibits tumor growth in nude mice AACR 93rd Annual Meeting April, 2002
93. Treatment of cancer with death receptor antibodies in combination with chemotherapy and radiation therapy. UAB/Sankyo Program for Rheumatic Diseases Research March, 2002
94. Striking antitumor efficacy of monoclonal antibodies to DR4 and DR5 with or without chemotherapy in a human breast cancer model. AACR Special Conference in Cancer Research - Apoptosis and Cancer February, 2002
95. TRA-8 studies in breast and ovarian cancer UAB/Sankyo Program for Rheumatic Diseases Research July, 2001
96. Treatment of human pancreatic cancer with IMC-C225 anti-EGFr antibody, gemcitabine, and radiation Treatment of human pancreatic cancer with IMC-C225 anti-EGFr antibody, gemcitabine, and radiation April, 2001
97. Biodistribution and imaging of pretargeted 125I-CC49sFv4/SA fusion protein and 111In-DOTA-biotin in an intraperitoneal tumor model The 8th Conference on Radioimmunodetection and Radioimmunotherapy of Cancer October, 2000
98. Biodistribution and imaging of pretargeted 125I-CC49sFv4/SA fusion protein and 111In-DOTA-biotin in an intraperitoneal tumor model 8th SPORE Investigators’ Workshop July, 2000
99. Biodistribution of HuCC49∆Ch2 labeled with 64Cu, 177Lu, or 188Re in an intraperitoneal tumor model. 12th International Conference on Monoclonal Antibodies for Cancer October, 1999
100. Development and testing of a herpes simplex virus encoding the gene for somatostatin receptor subtype 2 12th International Conference on Monoclonal Antibodies for Cancer October, 1999
101. Radiation therapy combined with cytosine deaminase gene delivery and 5-fluorocytosine enhances antitumor effects in human gastrointestinal and prostate cancer The 11th International Congress of Radiation Research July, 1999
102. Radioimmunoconjugates The Fifth International Society for Hematotherapy & Graft Engineering Annual Meeting May, 1999
103. Fractionated radiation with adenoviral delivery of the cytosine deaminase gene and 5-fluorocytosine enhances effects in human gastrointestinal cancer The American Radium Society 81st Annual Meeting April, 1999
104. Targeting strategies for cancer radiotherapy The Seventh Conference on Radioimmunodetection and Radioimmunotherapy of Cancer October, 1998
105. Comparison of multiple bolus and continuous injections of I-131-CC49 for therapy in a colon cancer xenograft model The Seventh Conference on Radioimmunodetection and Radioimmunotherapy of Cancer October, 1998
106. Application of type 2 human somatostatin receptor (hSSTr2) as a reporter for imaging gene transfer. The First International Symposium on Gene Imaging and Radio Gene Therapy, VI International Conference of Anticancer Research October, 1998
107. Genetic radioisotope targeting strategies for cancer localization and therapy The American Society of Gene Therapy 1st Annual Meeting May, 1998
108. Radiolabeled fusion toxin binding, cytotoxicity and localization to colon cancer cells induced to express IL-4 receptor The 89th Annual Meeting for AACR March, 1998
109. Evaluation of Ch2 deleted HuCC49 for intraperitoneal radioimmunotherapy Eleventh International Conference on Monoclonal Antibodies for Cancer March, 1998
110. Optimization of adenoviral induction of somatostatin receptor subtype 2 on human ovarian cancer xenografts as a target for radiolabeled octreotide localization and therapy The 89th Annual Meeting for AACR March, 1998
111. Radiolabeled DT390-mIL-4 fusion toxin binding and cytotoxicity to tumor cells induced to express mIL-4 receptor The Sixth International Conference on Gene Therapy of Cancer November, 1997
112. A gene transfer strategy to augment cancer radioimmunotherapy XXVth Anniversary Meeting of the International Society for Oncodevelopmental Biology and Medicine, September, 1997
113. A gene transfer strategy to augment cancer radioimmunotherapy Gordon Research Conference July, 1997
114. A gene transfer strategy to augment cancer radioimmunotherapy Gordon Research Conference June, 1997
115. Genetic induction of somatostatin receptor in tumor cells enhances binding and localization of radiolabeled octreotide The XIIth International Symposium on Radiopharmaceutical Chemistry June, 1997
116. A strategy to augment efficacy of genetic radiation immunotherapy by use of conditionally replication-enabled adenovirus Fifth International Conference on Gene Therapy of Cancer November, 1996
117. Experimental tumor targeting with radiolabeled ligands The Sixth Conference on Radioimmunodetection and Radioimmunotherapy of Cancer October, 1996
118. Genetic radioimmunotherapy of cancer Advances in the Applications of Monoclonal Antibodies in Clinical Oncology May, 1996
119. Strategies to augment radioimmunotherapy via genetic induction of receptors for radioligand binding Fourth International Conference on Gene Therapy of Cancer November, 1995
120. Targeted radioimmunotherapy and gene therapy radiation therapy initiative University of Alabama Cancer Center, External Advisory Committee Meeting June, 1995
121. Comparison of biodistribution of 131I-CC49 mAb in athymic nude mice bearing LS174T colon cancer xenografts following bolus injection or continuous infusion The Twelfth International Hammersmith Conference May, 1995
122. Methods to increase the therapeutic effect of radioimmunotherapy. Nuclear Oncology: Advances in Diagnostic and Therapeutic Applications January, 1995
123. Fractionated radioimmunotherapy of human colon carcinoma xenografts with 131I-CC49 monoclonal antibody e Fifth Conference on Radioimmunodetection and Radioimmunotherapy of Cancer, October, 1994
124. Epidermal growth factor receptor expression is modulated by tumor necrosis factor-a in human glioma cells 85th Annual Meeting of the American Association for Cancer Research April, 1994
125. Enhancement of EGF receptor expression in human malignant glioma cells by tumor necrosis factor-a. AACR Molecular Approaches to Cancer Immunotherapy Meeting November, 1993
126. 90Y-labeled 17-1A monoclonal antibody prepared using the new bifunctional chelating agent DOTA-NHS The Tenth International Symposium on Radiopharmaceutical Chemistry October, 1993
127. Sensitization of radiolabeled monoclonal antibody therapy using bromodeoxyuridine Fourth Conference on Radioimmunodetection and Radioimmunotherapy of Cancer September, 1992
128. Biodistribution and tumor growth inhibition of 131I-D612 MoAb in nude mice bearing LS174T colon cancer xenografts injected with IL-1a. 7th International Conference on Monoclonal Antibody Immunoconjugates for Cancer March, 1992
129. The potential for halogenated pyrimidines to increase the efficacy of radioimmunotherapy of colon cancer 9th International Congress of Radiation Research July, 1991
130. Radiolabeled monoclonal antibodies for the treatment of colon cancer. Advances in the Applications of Monoclonal Antibodies in Clinical Oncology May, 1991
131. Comparison of 131I- and 90Y-labeled MoAb 17-1A for treatment of human colon cancer xenografts Sixth Int Conference on Monoclonal Antibody Immunoconjugates for Cancer February, 1991
132. Factors affecting localization of radiolabeled anti-B1 antibody in lymphoma xenografts The Third Conference on Radioimmunodetection and Radioimmunotherapy of Cancer November, 1990
133. Immunotherapy with radiolabeled monoclonal antibodies 15th International Cancer Congress August, 1990
134. Therapy of human B-cell lymphoma xenografts with I-131-labeled B1 antibody The Society of Nuclear Medicine Thirty-seventh Annual Meeting, June, 1990
135. Binding and localization of 125I-labeled 425 antibody and F(ab')2 fragments to human glioma Forty-second Annual Meeting of the American Academy of Neurology May, 1990
136. Radioimmunoconjugate diagnosis and therapy of cancer University of Alabama Cancer Center June, 1989
137. Localization, imaging and therapy with radiolabeled B43 monoclonal antibody and fragments in nude mice bearing human B-cell lymphoma xenografts 4th Int Conf Monoclonal Antibody Immunoconjugates for Cancer March, 1989
138. Human chimeric and murine 17-1A monoclonal antibodies: binding to colon cancer cells and preclinical localization and therapy studies The Second Conference on Radioimmunodetection and Radioimmunotherapy of Cancer September, 1988
139. Radiolabeled monoclonal antibody localization and therapy in nude mice bearing human B-cell lymphoma 79th Annual Meeting of the American Association for Cancer Research May, 1988
140. Radiolabeled monoclonal antibody localization and therapy in vitro and in human cancer in nude mouse models Radiation Research Society April, 1988
141. Localization and imaging of radiolabeled monoclonal antibodies against colorectal carcinoma in nude mice bearing human tumor xenografts 3rd Int Conf Monoclonal Antibody Immunoconjugates for Cancer February, 1988
142. Radionuclide and drug immunoconjugates: Localization and therapy studies in human colon cancer nude mouse models Int Soc for Oncodevelopmental Biology and Medicine September, 1987
143. Leukemia cell binding and killing by CD5 radioimmunotoxins 2nd International Conference on Monoclonal Antibody Immunoconjugates for Cancer March, 1987
144. Tumor cell binding and killing by CD5 radioimmunotoxins 28th Annual Meeting of the American Society for Therapeutic Radiology and Oncology November, 1986
145. Localization of 125I-labeled tumor-specific antibodies in SVT2 tumor. 13th International Cancer Congress, September, 1982



Site wide Speaking/Presenting-Abstract/Poster at Mtg

No events found.
4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.